search

The most complex organ in humans is the brain. Due to its complexity and, of course, for ethical reasons, it is extremely difficult to do scientific experiments on it – ones that could help us to understand neurodegenerative diseases like Parkinson’s, for example. Scientists at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have now succeeded in turning human stem cells derived from skin samples into tiny, three-dimensional, brain-like cultures that behave very similarly to cells in the human midbrain.

In the researchers’ petri dishes, different cell types develop, connect into a network, exchange signals and produce metabolic products typical of the active brain. “Our cell cultures open new doors to brain research,” says Prof. Dr. Jens Schwamborn, in whose LCSB research group Developmental & Cellular Biology the research work was done. “We can now use them to study the causes of Parkinson’s disease and how it could possibly be effectively treated.” The team publishes its results today in the prestigious scientific journal “Stem Cell Reports”.

The human midbrain is of particular interest to Parkinson’s researchers: it is the seat of the tissue structure known medically as the substantia nigra. Here, nerve cells – specifically dopaminergic neurons – produce the messenger dopamine. Dopamine is needed to maintain smooth body movements. If the dopaminergic neurons die off, then the person affected develops tremors and muscle rigidity, the distinctive symptoms of Parkinson’s disease. For ethical reasons, researchers cannot take cells from the substantia nigra to study them. Research groups around the world are therefore working on cultivating three-dimensional structures of the midbrain in petri dishes. The LCSB team led by stem cell researcher Jens Schwamborn is one such group.

PLURIPOTENT STEM CELLS

The LCSB scientists worked with so-called induced pluripotent stem cells – stem cells that cannot produce a complete organism, but which can be transformed into all cell types of the human body. The procedures required for converting the stem cells into brain cells were developed by Anna Monzel as part of her doctoral thesis, which she is doing in Schwamborn’s group. “I had to develop a special, precisely defined cocktail of growth factors and a certain treatment method for the stem cells, so that they would differentiate in the desired direction,” Monzel describes her approach. To do this, she was able to draw on extensive preparatory work that had been done in Schwamborn’s team the years before. The pluripotent stem cells in the petri dishes multiplied and spread out into a three-dimensional supporting structure – producing tissue-like cell cultures.

STUDY THE MECHANISMS THAT LEAD TO PARKINSON’S DISEASE

“Our subsequent examination of these artificial tissue samples revealed that various cell types characteristic of the midbrain had developed,” says Jens Schwamborn. “The cells can transmit and process signals. We were even able to detect dopaminergic cells – just like in the midbrain.” This fact makes the LCSB scientists’ results of extraordinary interest to Parkinson’s researchers worldwide, as Schwamborn stresses: “On our new cell cultures, we can study the mechanisms that lead to Parkinson’s much better than was ever the case before. We can test what effects environmental impacts such as pollutants have on the onset of the disease, whether there are new active agents that could possibly relieve the symptoms of Parkinson’s – or whether the disease could even be cured from its very cause. We will be performing such investigations next.”

The development of the brain-like tissue cultures not only opens doors to new research approaches. It can also help to reduce the amount of animal testing in brain research. The cell cultures in the petri dishes are of human origin, and in some aspects resemble human brains more than the brains of lab animals such as rats or mice do. Therefore, the structures of human brains and its modes of function can be modelled in different ways than it is possible in animals. “There are also attractive economic opportunities in our approach,” Jens Schwamborn explains: “The production of tissue cultures is highly elaborate. In the scope of our spin-off Braingineering Technologies Sarl, we will be developing technologies by which we can provide the cultures for a fee to other labs or the pharmaceutical industry for their research.”

Read more

10 key technologies shaping the post COVID-19 economy

16-09-2020

The COVID-19 pandemic has changed our ways of living, working, consuming and travelling, and has had a huge impact on companies’ and consumers’ use of technology. Luxinnovation lists 10 key technologies that will play a crucial role in the economy over the months and years to come.
Read more

Solutions for rapid improvements in understanding, mitigating and responding to the pandemic

19-05-2020

The European Commission (EC) has launched several Research and Innovation actions through its main research framework Horizon 2020 to address the COVID-19 crisis.
Read more

Eureka Calls 2020

06-05-2020

Luxembourg is participating this year in three Eureka calls for projects as a funding country, in the fields of advanced materials, healthy ageing and AI.
Read more

National call for COVID-19 research projects open to public-private partnerships

28-04-2020

The call for research projects addressing current and future challenges of COVID-19 launched by the Luxembourg National Research Fund (FNR) is now open to public-private partnerships involving companies and research institutions. The participation of companies will be co-funded by the Ministry of the Economy. Luxinnovation will advise companies on their participation and provide support to the proposal evaluation process.
Read more

From spin-off to technology platform: the MPG story

22-04-2020

Take a completely unique molecular plasma technology and combine it with a visionary team. Place them in a nurturing national ecosystem, and you have the main ingredients of the success story of Molecular Plasma Group. The Luxembourg start-up is about to make a major international breakthrough.
Read more

All news

Close